Skip to main content
. Author manuscript; available in PMC: 2021 Dec 24.
Published in final edited form as: J Med Chem. 2020 Dec 16;63(24):16012–16027. doi: 10.1021/acs.jmedchem.0c01874

Table 1.

Receptor-Binding Profiles of Truncated 1′-Homologated Adenosine Derivatives 4a–4t

graphic file with name nihms-1711262-t0002.jpg
cpd X Y R hA3AR Ki (nM) or % replacementa PPARα % replacementb at 30 μM (%) PPARγ Ki (μM) or % replacementb PPARδ Ki (μM) or % replacementb
1 4.16 35.6 3.33 ± 1.67 0.0106 ± 0.015
4a S Cl F 17% at 10 μM 15.5 3.89 ± 0.47 1.91 ± 0.39
4b S Cl Cl 13% at 10 μM 12.8 34.1% at 30 μM 7.8% at 30 μM
4c S Cl Br 21% at 10 μM 3.0 4.07 ± 0.86 0.592 ± 0.26
4d S Cl I 10% at 10 μM 20.4 1.23 ± 0.25 0.106 ± 0.031
4e S H F 9% at 10 μM 25.6 24.4% at 30 μM 0.8% at 30 μM
4f S H Cl 9% at 10 μM 7.7 24.9% at 30 μM 10.0% at 30 μM
4g S H Br 6% at 10 μM 5.4 33.5% at 30 μM 9.9% at 30 μM
4h S H I 14% at 10 μM 9.4 39.2% at 30 μM 5.2% at 30 μM
4i S −C≡CCH3 F 2% at 10 μM 15.5 7.66 ± 0.65 13.8% at 30 μM
4j S −C≡CCH3 Cl 1% at 10 μM 12.6 41.7% at 30 μM 3.8% at 30 μM
4k S −C≡CCH3 Br 12% at 10 μM 12.8 7.04 ± 0.40 15.3% at 30 μM
4l S −C≡CCH3 I 2% at 10 μM 24.0 7.30 ± 1.01 15.9% at 30 μM
4m O Cl F 2% at 10 μM 5.0 9.0% at 30 μM 7.3% at 30 μM
4n O Cl Cl 1% at 10 μM 3.6 7.66 ± 2.45 0.504 ± 0.29
4o O Cl Br 14% at 10 μM 23.2 9.55 ± 6.61 1.43 ± 0.67
4p O Cl I 3% at 10 μM 0.3 3.56 ± 0.75 0.374 ± 0.036
4q O H F 1% at 10 μM 1.4 13.3% at 30 μM 14.6% at 30 μM
4r O H Cl 1% at 10 μM 8.3 0.8% at 30 μM 10.6% at 30 μM
4s O H Br 14% at 10 μM 5.6 4.1% at 30 μM 16.5% at 30 μM
4t O H I 3% at 10 μM 1.7 16.0% at 30 μM 6.5% at 30 μM
26 ND 3.5 0.096 ± 0.049 14.7% at 30 μM
27 ND 44.9 38.5% at 30 μM 0.00608 ± 0.0055
28 ND 12.4 59.9% at 30 μM 0.00465 ± 0.0023
a

Binding affinities of 4a4h to human A3 AR were previously reported.6,23

b

Binding affinities to PPARs were determined based on TR-FRET-based PPAR competitive binding assays. Ki, inhibition constant; ND, not determined.